News | Heart Failure | April 26, 2021

Socioeconomic Disparities Associate With Epigenetics and Heart Failure Outcomes

UAB study identifies new link between race and heart failure severity

Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology

Image courtesy of the American Journal of Physiology.

April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States. Heart failure disproportionately affects African Americans who are 30 percent more likely to die from heart disease than non-Hispanic Caucasian Americans. Despite this, relatively little is known as to why these differences in outcomes exist and what mechanisms might be targeted for individualized therapies. 

Researchers at the University of Alabama at Birmingham in the Department of Pathology have now identified an association between molecular programming of gene expression through epigenetics and socioeconomic disparities. The research team, led by Adam R. Wende, Ph.D., associate professor of molecular and cellular pathology, has focused work from his laboratory specifically on DNA methylation. These modifications that occur across the genome alter mRNA transcriptional regulation. Specifically, DNA methylation at the promoter regions of genes is inversely related to their expression. Epigenetic modifications can be inherited, but they also change in response to environmental influences such as diet, exercise, pollution and stress.

The Wende lab-led study, now published in American Journal of Physiology – Heart and Circulatory Physiology, has been highlighted with both a cover and editorial providing additional insight.[1]

Previously, Wende’s group assisted in a study that identified links between DNA methylation in all cause heart failure associated with the ability to use different metabolic fuels to maintain contractility, namely a decrease in oxidative metabolism.[2] An additional study from the group found molecular mechanisms specific to ischemic heart failure, which identified a key epigenetic regulator (i.e. EZH2) as likely having an active role in gene expression regulation involved in both metabolic and structural remodeling.[3] 

In the new study highlighted here, the research group and lead investigator, former Medical Scientist Training Program (MSTP) student Mark E. Pepin, M.D., Ph.D., followed up on an observation in the prior ischemia study which pointed to the fact that the greatest differences in DNA methylation in their patient population were between race. The group then received funding from the NIH-funded Center for Healthy African American Men through Partnerships (CHAAMPS) to expand this research. 

 

Cardiac Biopsy Samples Taken From LVAD Cores for This Study

Their study examined cardiac tissue collected at UAB during left ventricular assist device (LVAD) placement. These tissue cores are removed from heart failure patients to place the LVAD pump which helps unload failing hearts, often in patients as they await heart transplant. In total the new analysis focused on 31 additional male patients aged 49–70 years. Wende’s laboratory uses this human material to examine gene expression through RNA-sequencing and DNA methylation through the Illumina Infinium MethylationEPIC array. Pepin used these transcriptomic and methylomic data sets to run several bioinformatic analyses. 

The result was identification of distinct signatures in genome-wide methylation which were then linked to different gene expression pathways. These were distinctly different between the African American and non-Hispanic Caucasian American patients, with inflammatory pathways showing marks that would suggest easier activation in African Americans. Additional analysis by the students and co-authors in Wende’s laboratory with the assistance of another laboratory at UAB in the Department of Epidemiology run by Bertha A. Hidalgo, Ph.D., further showed that these differences in epigenetics were associated with regional poverty and patient survival.

Although preliminary in nature, this study highlights the need for more research in this area as well as follow up studies to determine if any of these molecular marks could represent therapeutic targets for the patients most robustly affected by heart failure.

 

Related Content on New Technology and Ideas to Address Health Disparities:

VIDEO: New Ideas in Addressing Cardiovascular Disease Disparities — Clyde Yancy, M.D

5 Technologies to Help Overcome Healthcare Disparities in the Next Decade

VIDEO: How Smartphones May Revolutionize Healthcare in the Developing World —Interview with Jacques Kpodonu, M.D.

VIDEO: Reducing Hypertension Among African-Americans — Interview with Kim Allan Williams, Sr., M.D.

VIDEO: New PLATINUM Diversity Data Shows Early DAPT Cessation OK in Minorities With New Generation Stent — Interview with Roxana Mehran, M.D., where she explains how trials can be designed to better include minorities. 

 

VIDEO: Use of Wearable Medical Devices for Cardiac Rehabilitation — Interview with Robert Klempfner, M.D.

VIDEO: Use of Wearables to Track Electrophysiology Patients — Interview with Khaldoun Tarakji, M.D.

COVID-19 Cardiovascular Registry Details Disparities Among Hospitalized Patients

Study Finds Removing Cost from Calcium Score Testing Increased Utilization

 

Blacks Have Higher Mortality After PCI

Link Shown Between Economic Disparities and Cardiovascular Death in Middle-Aged Adults

VIDEO: Using an iPhone to Perform a Cardiac Ultrasound Exam
 

References:

1. Mark E. Pepin, Chae-Myeong Ha, Luke A. Potter, Sayan Bakshi, Joseph P. Barchue, Ayman Haj asaad, Steven M. Pogwizd, Salpy V. Pamboukian, Bertha A. Hidalgo, Selwyn M. Vickers, and Adam R. Wende. Racial and socioeconomic disparity associates with differences in cardiac DNA methylation among men with end-stage heart failure. American Journal of Physiology-Heart and Circulatory Physiology, March 26, 2021. https://doi.org/10.1152/ajpheart.00036.2021.

2. Mark E. Pepin, Stavros Drakos, Chae-Myeong Ha, Martin Tristani-Firouzi,et al.DNA methylation reprograms cardiac metabolic gene expression in end-stage human heart failure. Heart and Circulatory Physiology. 19 SEP 2019. https://doi.org/10.1152/ajpheart.00016.2019.

3. Mark E. Pepin, Chae-Myeong Ha, David K. Crossman, et al. Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure. Laboratory Investigation volume 99, pages371–386(2019). 

 

Related Content

Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium.

Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium. 

News | Cardiovascular Clinical Studies | January 27, 2021
January 27, 2021 — A New York Institute of Technology research te
Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di